ijms-logo

Journal Browser

Journal Browser

Molecular Perspective in Autoimmune Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 20 October 2025 | Viewed by 751

Special Issue Editors


E-Mail Website
Guest Editor
Internal Service, Hospital Universitario Ramón y Cajal, Irycis, 28034 Madrid, Spain
Interests: systemic lupus erythematosus; autoimmune disease; autoinflammatory disease; Castleman’s disease; vasculitis; IgG4RD
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Dermatology Service, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Carretera de Colmenar Km 9, 28034 Madrid, Spain
Interests: dermatology; photodermatology; complex skin diseases; phototherapy; photodynamic therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, research into autoimmune and autoinflammatory diseases has increasingly focused on uncovering the molecular mechanisms that drive these complex diseases. Despite significant progress, many of the genetic and molecular factors involved remain elusive. This Special Issue, titled “Molecular Perspective in Autoimmune Diseases”, will highlight cutting-edge research that advances our understanding of the molecular bases of autoimmune diseases.

We invite submissions that explore a range of topics, including the following:

  • Genetic variation: Detailed studies of SNPs, CNVs, and mutations associated with autoimmune and autoinflammatory diseases;
  • Interferon pathway in several diseases such as systemic lupus erythematosus, systemic sclerosis, Sjögren syndrome, and other inflammatory diseases;
  • Functional Mechanisms: Investigating the molecular pathways and mechanisms involved in autoimmune pathogenesis;
  • Role of cytokines and their link with more uncommon systemic and hyperinflammatory states like hemophagocytic lymphohistiocytosis, idiopathic multicentric Castleman’s disease, catastrophic antiphospholipid syndrome, etc.;
  • Novel developments in inflammatory diseases and other human inborn errors of immunity.

Both original research articles and reviews are welcome if they provide a comprehensive perspective on these molecular findings and their implications for advancing the diagnosis and treatment of autoimmune diseases.

We look forward to receiving your valuable submissions.

Dr. Andrés González-García
Dr. Montserrat Fernández-Guarino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interferon
  • cytokines
  • lupus nephritis
  • lupus
  • type I interferon
  • vasculitis
  • IgG4-related disease
  • B cell
  • NETs
  • IL-6
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3034 KiB  
Article
Topical miRNA Delivery via Elastic Liposomal Formulation: A Promising Genetic Therapy for Cutaneous Lupus Erythematosus (CLE)
by Blanca Joseph-Mullol, Maria Royo, Veronique Preat, Teresa Moliné, Berta Ferrer, Gloria Aparicio, Josefina Cortés-Hernández and Cristina Solé
Int. J. Mol. Sci. 2025, 26(6), 2641; https://doi.org/10.3390/ijms26062641 - 14 Mar 2025
Viewed by 485
Abstract
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune skin disorder with limited therapeutic options, particularly for refractory discoid lupus (DLE), which often results in scarring and atrophy. Recent studies have identified miR-31, miR-485-3p, and miR-885-5p as key regulators of inflammation, apoptosis, and fibrosis [...] Read more.
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune skin disorder with limited therapeutic options, particularly for refractory discoid lupus (DLE), which often results in scarring and atrophy. Recent studies have identified miR-31, miR-485-3p, and miR-885-5p as key regulators of inflammation, apoptosis, and fibrosis in CLE skin lesions. This research investigates a novel topical miRNA therapy using DDC642 elastic liposomes to target these pathways in CLE. DDC642 liposomes were complexed with miRNAs (anti-miR-31, anti-miR-485-3p, pre-miR-885-5p) and characterized through dynamic light scattering and Cryo-TEM. Cytotoxicity, cellular penetration, and therapeutic efficacy were evaluated in primary keratinocytes, PBMCs, and immune 3D-skin organoids. miRNA lipoplexes were successfully synthesized with optimized particle size, surface charge, and encapsulation efficiency. These lipoplexes exhibited effective cellular penetration and low cytotoxicity. Anti-miR-31 lipoplexes reduced miR-31 and NF-κB levels while increasing STK40 and PPP6C expression. Pre-miR-885-5p lipoplexes elevated miR-885-5p levels and downregulated PSMB5 and NF-κB in keratinocytes. While anti-miR-485-3p lipoplexes reduced T-cell activation markers. Anti-miR-31 and pre-miR-885-5p lipoplexes successfully modulated inflammatory pathways in 3D-skin CLE models. miRNA lipoplexes represent promising candidates for pioneering topical genetic therapies for CLE. Further studies, including animal models, are necessary to validate and optimize these findings. Full article
(This article belongs to the Special Issue Molecular Perspective in Autoimmune Diseases)
Show Figures

Figure 1

Back to TopTop